Ring 1
Ring 2
Ring 3
Ring 4

Vedanta Biosciences

Financing Rounds

  • Series C
  • Series D+
Round Led by Symbiosis
Round Led by Symbiosis

Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy.

vedanta View Website


  • Biologic


  • Gastroenterology
  • Immunology
  • Infectious Disease
  • Oncology

Development Status

  • Phase 2

Learn More About Vedanta Biosciences